Effect of oral P10358 and HEP on dopaminergic parameters in rat striatum
| Treatment | Percent of Control | ||
|---|---|---|---|
| DA | DOPAC | HVA | |
| Control | 100 ± 5 | 100 ± 4 | 100 ± 14 |
| P10358, 5 mg/kg | 96 ± 10 | 90 ± 10 | 126 ± 31 |
| P10358, 20 mg/kg | 89 ± 7 | 97 ± 12 | 166 ± 252-a |
| HEP, 10 mg/kg | 108 ± 4 | 100 ± 16 | 137 ± 142-a |
| MOCLO, 10 mg/kg | 126 ± 12 | 26 ± 32-a | 36 ± 82-b |
| TRANYLCYP, 5 mg/kg | 133 ± 18 | 12 ± 122-b | 02-b |
Fasted male Wistar rats (n = 5–6) were pretreated with oral P10358 (1 hr), HEP (2 hr), MOCLO (2 hr) or TRANYLCYP (2 hr) before death. The different doses and treatment times were used to achieve comparable degrees of AChE or MAO inhibition in the striatum. Basal values of DA, DOPAC and HVA in the control group were 368 ± 19, 73 ± 3 and 36 ± 5 pmol/mg protein, respectively. The inhibition of striatal AChE activity in the 5 and 20 mg/kg P10358 and the HEP groups were 37 ± 4, 66 ± 8 and 60 ± 5%, respectively.
↵2-a P < .05 compared to control (unpaired ttest).
↵2-b P < .01 compared to control (unpaired ttest).